In the current mini-review, we present a short overview of genetic as well as immunohistochemical p14(ARF) alterations either in primary human endometrial carcinomas (ECs) or in metastatic lesions originated from malignant endometrium. The prognostic utility of p14(ARF) in uterine malignancies has also been briefly discussed.